Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Adenovirus specific T cells Cell Medica (Primary)
- Indications Adenovirus infections
- Focus Adverse reactions
- Acronyms ASPIRe
- Sponsors Cell Medica
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 08 Jul 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2016.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.